+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Psoriasis: Update Bulletin [January 2018]

  • ID: 4521363
  • Newsletter
  • January 2020
  • Region: Global
  • FirstWord Publishing
1 of 1

This edition presents key opinion leader (KOL) views on recent developments in the Psoriasis market. Topics covered include: Initiation of thePhase III BE VIVID trial for UCB’s bimekizumab (CDP-4940); Approval of Tremfya (guselkumab; Janssen Biotech/MorphoSys) in the EU; Initiation of a Phase II clinical trial for Affibody’s ABY-035; Top-line results from the Phase III IMMhance trial for risankizumab (BI 655066; ABBV-066; Boehringer Ingelheim/AbbVie).

Business Questions:
  • Is bimekizumab’s dual anti-IL-17A/IL-17F activity likely to provide it with any clinical advantage over other IL-17A inhibitors and do current data reflect this?
  • If approved, where do KOLs think bimekizumab will be positioned within the psoriasis treatment paradigm?
  • How does Tremfya compare with other treatments for psoriasis, and will Janssen Biotech need to take any additional steps to help differentiate it?
  • Following its recent European approval, where is Tremfya likely to be positioned within the psoriasis treatment algorithm?
  • How might the usage of Tremfya evolve in the months following launch?
  • As a novel affibody-type drug, is ABY-035 expected to offer any advantages over other psoriasis therapies in terms of safety and efficacy?
  • Do KOLs think that Affibody has the necessary commercial leverage to successfully market ABY-035?
  • If approved, which factors are likely to determine the positioning and uptake of ABY-035 within the psoriasis market?
  • Following the completion of its Phase III trial programme, how do KOLs think risankizumab compares with Tremfya in terms of safety and efficacy?
  • What will AbbVie have to do in order to differentiate risankizumab from other psoriasis therapies?
Note: Product cover images may vary from those shown
2 of 1